Evidence map›Paper›PMID 37289062›Full record

ArticleMicrobiology spectrum2023

Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis.

Rachel F Rollo, Giorgia Mori, Timothy A Hill, Doris Hillemann, Stefan Niemann, Susanne Homolka, David P Fairlie, Antje Blumenthal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Rachel F RolloFrazer Institute, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-3984-1184
Giorgia MoriFrazer Institute, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-3469-5632
Timothy A HillInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0001-9727-9930
Doris HillemannNational and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Stefan NiemannMolecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.ORCID 0000-0002-6604-0684
Susanne HomolkaMolecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.ORCID 0000-0003-4972-5638
David P FairlieInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-7856-8566
Antje BlumenthalFrazer Institute, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-3673-7015
The University of Queensland · AUAustralian Research Council · AUResearch Center Borstel - Leibniz Lung Center · DEGerman Center for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shorter and more effective treatment regimens as well as new drugs are urgent priorities for reducing the immense global burden of tuberculosis (TB). As treatment of TB currently requires multiple antibiotics with diverse mechanisms of action, any new drug lead requires assessment of potential interactions with existing TB antibiotics. We previously described the discovery of wollamides, a new class of

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsEthambutolHumansMicrobial Sensitivity TestsNitroimidazolesAntitubercular AgentsEthambutolNitroimidazolespretomanidantimicrobial combinationsmultidrug resistanceMycobacterium tuberculosis

Identifiers

PMID37289062
PMCPMC10433873
OpenAlexW4379769352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.